Introduction {#Sec1}
============

Bone fractures, malformations, surgical removal of tumors and periodontitis can cause bone defects that interfere with normal bone function and configuration and have become serious clinical problems. Regeneration of damaged bone tissue has been a major goal for both clinicians and researchers worldwide. Currently, autologous and allogenic bone grafts are the primary treatment modalities. However, clinical application of these bone grafts is limited due to the high cost of bone-harvesting procedures and are associated with donor site morbidity, inflammation, and pain^[@CR1],\ [@CR2]^.

Bone tissue engineering provides several advantages, including high-quality regeneration of damaged tissues, no donor site harvesting, and low risk of disease transmission or autoimmune rejection^[@CR3]^. Studies have shown that dental-derived mesenchymal stem cells (MSCs) may have superior differentiation capacity compared with human bone marrow mesenchymal stem cells (hBMMSCs)^[@CR4]--[@CR7]^. Among the different types of dental MSCs that have been identified thus far, stem cells from periodontal ligaments (PDLSCs) are of special interest. Studies have confirmed the multilineage differentiation capacity of PDLSCs *in vitro* and *in vivo*, which suggests that PDLSCs are ideal cell sources for cell-based periodontal/bone regeneration therapy^[@CR8]--[@CR10]^.

In addition to directly differentiating into bone- forming cells, MSCs also enhance blood vessel regeneration and vascularization, which is crucial for bone regeneration and survival of newly formed bone tissues. CXCL12 (also known as SDF-1) is a chemokine that regulates bone marrow-derived mesenchymal stem/stromal cells (BMSCs) migration by interacting with CXCR4^[@CR11],\ [@CR12]^. However, recent studies have also shown that the CXCL12 not only regulates cell migration but also promotes angiogenesis in damaged tissue^[@CR13],\ [@CR14]^. CXCL12 has been reported to induce neovascularization in ischemic lesion, tumor, and wounded tissues^[@CR15]--[@CR17]^. In addition, CXCL12 acts synergistically with vascular endothelial growth factor (VEGF) to enhance angiogenesis^[@CR18],\ [@CR19]^. Therefore, it is reasonable to hypothesize that CXCL12 overexpression can potentiate PDLSC angiogenesis.

Here, to test our hypothesis, we investigated whether CXCL12 can enhance PDLSC-mediated angiogenesis and bone tissue repair through *in vitro* and *in vivo* studies.

Results {#Sec2}
=======

Mesenchymal stem cell markers expression and multilineage differentiation potential of PDLSCs {#Sec3}
---------------------------------------------------------------------------------------------

The flow cytometry analysis (Supporting Fig. [S1A](#MOESM1){ref-type="media"}) showed that PDLSCs expressed mesenchymal stem cells markers, like CD90, CD44 and CD105. CD45 was not detected.

The results of Oil Red O (Supporting Fig. [S1B](#MOESM1){ref-type="media"}) and alkaline phosphatase (Supporting Fig. [S1C](#MOESM1){ref-type="media"}) staining showed that PDLSCs possessed multilineage differentiation potential.

CXCL12 overexpression enhances angiogenesis of PDLSCs *in vitro* {#Sec4}
----------------------------------------------------------------

To assess the effect of CXCL12 overexpression on promoting angiogenesis potential, PDLSCs were transduced with Lenti-CXCL12-GFP and Lenti-GFP. The mRNA and protein levels of angiogenesis-associated factors were measured at post-transduction day 1, 4, 7, and 14. The mRNA expression of VEGF, which involves the regulation of blood vessel formation, was significantly increased on post-transduction day 4 in CXCL12-transduced PDLSCs and continued to increase at day 7 and day 14 compared with GFP control group (Fig. [1A](#Fig1){ref-type="fig"}). The expression level of other critical angiogenic genes, such as basic fibroblast growth factor (bFGF), placental growth factor (PLGF) and stem cell factor (SCF), showed a general tendency identical to that of VEGF. The protein expression of angiogenic markers in gene modified PDLSCs exhibited the same trend as that observed with qPCR. The expressions of VEGF, SCF bFGF and PLGF protein increased obviously from day 7 in Lenti-CXCL12-transduced group compared with control (Fig. [1B](#Fig1){ref-type="fig"}). These data indicated that CXCL12 overexpression potentiate mRNA and protein expression of angiogenic markers in PDLSCs *in vitro*.Figure 1Quantitative RT-qPCR and Western-blot analysis of angiogenesis-associated factors in CXCL12 modified PDLSCs. PDLSCs were transduced with Lenti-CXCL12-GFP and Lenti-GFP and mRNA (**A**) and protein (**B**) levels of angiogenesis-associated factors were measured by RT-qPCR and Western blot assays respectively at post-transduction day 1, 4, 7 and 14. All experiments were performed three times (N = 3). \**p* \< 0.05.

To further investigate whether CXCL12-modified PDLSCs possess angiogenic function, the *in vitro* Matrigel angiogenesis assay was performed. Lenti-GFP/PDLSCs, Lenti-CXCL12-GFP/PDLSCs, and PDLSCs were seeded onto Matrigel, and vascular-like structures were evaluated. The resulting vessel-like structures were shown in Fig. [2](#Fig2){ref-type="fig"}. Image analysis demonstrated a significant increase in tubule length in the Lenti-CXCL12-GFP/PDLSCs at 48 h compared with the other control groups, which quantitatively demonstrated the angiogenesis-facilitating effect.Figure 2The vessel-like structure formation by CXCL12 modified PDLSCs on the surface of Matrigel. PDLSCs, Lenti-GFP/PDLSCs and Lenti-CXCL12-GFP/PDLSCs were seeded (2 × 10^4^ cells/well) in 96-well plates coated with Matrigel and images were captured at 4 h and 48 h (**A**); statistical analysis showed longer vessel-like structure formation in Lenti-CXCL12-GFP/PDLSCs than in PDLSCs and Lenti-GFP/PDLSCs (**B**). \**p* \< 0.05.

CXCL12 promoted PDLSCs bone regeneration and angiogenic potential in a rat critical-sized calvarial defect model {#Sec5}
----------------------------------------------------------------------------------------------------------------

Two bilateral 5 mm diameter critical-sized calvarial defects were created in rats and filled with β-TCP, Lenti-CXCL12-GFP/PDLSCs/β-TCP, Lenti-GFP/PDLSCs/β-TCP group, PDLSCs/β-TCP group respectively. Eight weeks later, the rats were sacrificed and specimens of bone defects examined by histology and immunohistochemistry. The results of hematoxylin and eosin (HE) staining of decalcified specimens showed that the percentage of new bone formation area was significantly higher in the Lenti-GFP/PDLSCs/β-TCP group (0.118 ± 0.013) than that in the β-TCP group (0.038 ± 0.014), while compared with that in the Lenti-GFP/PDLSCs/β-TCP group, 2 times more new bone could be detected in the Lenti-CXCL12-GFP/PDLSCs/β-TCP group (0.225 ± 0.021). By contrast, there was no significant difference between the β- Lenti-GFP/PDLSCs/β-TCP group and PDLSCs/β-TCP group (Fig. [3](#Fig3){ref-type="fig"}).Figure 3The bone regeneration potential of CXCL12 modified PDLSCs in a rat critical-sized calvarial defects model. Lenti-CXCL12-GFP/PDLSCs/β-TCP, Lenti-GFP/PDLSCs/β-TCP, PDLSCs/β-TCP and β-TCP were respectively grafted into rat critical-sized calvarial defects for 8 weeks. HE staining for specimens of bone defects was conducted (**A**) and a new bone formation percentage accounted (**B**). \**p* \< 0.05, ^\#^ *p* \< 0.05.

Morphology of the newly formed bone was also detected by micro-CT. Substantial formation of plate-like bone structures was visible in the defect site 8 weeks after treatment with target gene-transduced PDLSCs. The new bone had expanded and occupied almost the whole region of the bone defect observed by coronal and sagittal surface (Fig. [4A](#Fig4){ref-type="fig"}). Quantitative analysis of the newly formed bone was performed using morphometrical methods. This analysis confirmed that more bone formation occurred in the target gene groups (\**p* \< 0.05). The ratio of new BV to total BV (BV/TV, %), which indicates the relative amount of newly formed bone, was 45.68% in the Lenti-CXCL12-GFP/PDLSCs/β-TCP group, 18.45% in the Lenti- GFP/PDLSCs/β-TCP group, 17.29% in the PDLSCs/β-TCP group, and 9.52% in theβ-TCP group (Fig. [4B](#Fig4){ref-type="fig"}). Local BMDs demonstrated the same tendencies that bone formation was more in the target gene groups than the control group (Fig. [4C](#Fig4){ref-type="fig"}).Figure 4Micro-CT evaluation of the repaired skull at 8 weeks after implantation. β-TCP group, PDLSCs/β-TCP group, Lenti-GFP/PDLSCs/β-TCP group and Lenti-CXCL12-GFP/PDLSCs/β-TCP group. (from left to right). Micro-CT images of calvarial defects taken 8 weeks after implantation (**A**). Morphometric analysis of new bone formation (**B**) and local bone mineral density (**C**). \**p* \< 0.05.

Similar trends can be observed in the immunohistochemistry assays. It is revealed that there were stronger expressions of VEGF, PLGF, bFGF and SCF in Lenti-CXCL12-GFP/PDLSCs/β-TCP group than that in the other three groups (Fig. [5](#Fig5){ref-type="fig"}).Figure 5The angiogenesis potential of CXCL12 modified PDLSCs in a rat critical-sized calvarial defects model. Lenti-CXCL12-GFP/PDLSCs/β-TCP, Lenti-GFP/PDLSCs/β-TCP, PDLSCs/β-TCP and β-TCP were respectively grafted into rat critical-sized calvarial defects for 8 weeks and expressions of angiogenic markers in specimens of bone defects were examined with IHC (**A**) and quantitatively analyzed (**B**). All experiments were performed six times (N = 6). \**p* \< 0.05, ^\#^ *p* \< 0.05.

Discussion {#Sec6}
==========

Previous studies have reported on the many disadvantages associated with current bone regeneration treatment modalities in craniofacial reconstructive surgery and regenerative medicine^[@CR20]--[@CR22]^. We demonstrate here that CXCL12 can enhance the expression of several growth factors associated with angiogenesis when transduced into PDLSCs. This approach shows promise as a therapeutic option and does not suffer from the drawbacks of current bone regeneration techniques^[@CR23]--[@CR25]^. Periodontal ligament tissue provides a superior source of MSCs owing to their accessibility and availability for autologous transplantation^[@CR7],\ [@CR23]^. Using human PDLSCs for tissue regeneration might be a promising cellular-based modality for bone tissue engineering. However, according to the results of the current study, transplanted PDLSCs only result in mild bone regeneration capacity.

CXCL12 has been extensively studied, including its roles in migration, homing, proliferation, and angiogenesis^[@CR11],\ [@CR16],\ [@CR26]--[@CR29]^. Many studies have shown that BMSCs can migrate to injured tissues via the CXCL12/CXCR4 axis and relieve myocardial infarction^[@CR11],\ [@CR30]^, promote wound healing^[@CR17]^, heal bone fracture^[@CR31]^, and reduce cerebral ischemia^[@CR32]^. CXCL12 expression is upregulated by hypoxia-inducible factor-1 (HIF-1)^[@CR33]^, and the CXCL12/CXCR4 axis has been shown to stimulate BMSCs to express VEGF, ANG-1, HGF, and TGF-β, promoting further angiogenesis *in vitro*. VEGF, a potent inducer of angiogenesis, promotes the repair of injured vascular endothelial cells and neovascularization. Studies have shown that CXCL12 promotes the synthesis and secretion of VEGF, and CXCL12 combined with VEGF enhances ischemic angiogenesis^[@CR15],\ [@CR18],\ [@CR34]^.

In our study, we demonstrate that CXCL12 can enhance the expression of VEGF, PLGF, bFGF and SCF genes *in vitro*. Similar trends were also observed in western blotting and Matrigel experiments. To determine whether CXCL12 improves bone regeneration and plays an important role in angiogenesis *in vivo*, PDLSCs were transplanted into critical-sized calvarial bone defects. We found that CXCL12 induced angiogenesis and the expression of VEGF, PLGF, bFGF and SCF in the regenerated bone was higher in the Lenti-CXCL12-GFP/PDLSCs/β-TCP group than in the control groups. Taken together, the results showed that transplanted PDLSCs transduced with CXCL12 repaired the damaged bone tissue by secreting a large number of cellular growth factors.

CXCL12 levels have been reported to be increased at both the mRNA and protein levels during bone graft repair, and anti-SDF-1 (CXCL12) antibody inhibited new bone formation^[@CR35]^. Moreover, Jones *et al*. demonstrated in a murine osteogenesis imperfecta model that MSC migration to bone and bone marrow is CXCL12-dependent and that CXCL12 upregulates CXCR4, demonstrating chemotaxis *in vitro* and enhancing engraftment *in vivo* ^[@CR36]^. Inflammation and hypoxia play an important role in regulating the SDF-1/CXCR4 axis. Therefore, we will further investigate whether the effect of CXCL12 on the induction of BMSC migration contributes to the results obtained from the *in vivo* experiment.

Methods {#Sec7}
=======

PDLSCs isolation and culture {#Sec8}
----------------------------

Human PDLSCs were isolated and cultured according to previously published protocols by Seo *et al*.^[@CR5]^ and Zhang *et al*.^[@CR7]^. Teeth and periodontal ligament tissues were obtained from healthy male patients (18--25 years old) without any history of periodontal disease who were undergoing third molar extractions. Written informed consent was provided by all patients, and ethical approval was obtained from the Ethics Committee of the School of Stomatology, Shandong University. Briefly, periodontal ligament tissues were gently separated from the surface of the root and digested in the solution of collagenase type I (Worthington Biochem) and dispase (Roche) for 1 h at 37 °C. Single-cell suspensions were obtained by passing the cells through a 70 µm filter. To identify the PDLSCs, single-cell suspensions (1 × 10^4^ cells) were seeded into 10-cm culture dishes (Costar) with α minimum essential medium (αMEM) (Gibco BRL) supplemented with 10% fetal calf serum (Gibco, Inc.), 100 mM ascorbic acid 2-phosphate (Sigma-Aldrich), 2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (Sigma-Aldrich) and then incubated at 37 °C in 5% CO~2~.

PDLSCs Multi-differentiation {#Sec9}
----------------------------

PDLSCs were cultured in DMEM (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin. To induce osteoblast differentiation, primary UCBMSCs were grown to confluence in 6-well plates, and the medium was supplemented with calcifying agents (vitamin C, beta-glycerophosphate, and dexamethasone). Cells cultured for up to 28 days were used to assess biomineralization using alkaline phosphatase (ALP) staining (Sigma-Aldrich). For adipogenesis, a specific adipogenesis medium was used (Cyagen, China) and oil red O staining were used to detect the result.

Flow cytometry {#Sec10}
--------------

PDLSC were harvested and fixed in 4% paraformaldehyde-phosphate buffer for 20 min. Blocking was performed in PBS containing 2% bovine serum albumin and 0.02% Triton-X 100. After washing with 2% fetal bovine serum-PBS, 2 × 10^5^ cells were stained with the following antibodies for 60 min. Mouse anti-human PE-conjugated CD146 and CD105 antibody (BD Bioscience CA); Mouse anti-human APC-conjugated CD90 antibody (BD Bioscience CA);Mouse anti-human FITC-conjugated CD44 and CD45 (1:10; BD Bioscience); All flow cytometry tests were performed on a FACS Aria (BD Bioscience).

Cell Transduction {#Sec11}
-----------------

PDLSCs were passaged until the third generation and then transduced with a lentivirus. The control vector was a replication-defective lentivirus encoding GFP (Lenti-GFP). Large-scale lentiviral production was performed by Shanghai R&S Biotechnology Co., Ltd. (Shanghai, China). The efficiency of lentiviral gene transfer in PDLSCs was greatest when the multiplicity of infection (MOI) was 8. The transduction efficiency was assessed by determining the fluorescence intensity after 4 d of culture.

Real‐time PCR Assay {#Sec12}
-------------------

For RT-qPCR analysis, total RNA was extracted using TRIzol (Sigma-Aldrich, USA). cDNA synthesis was performed using a PrimeScript RT kit following the manufacturer's instructions (Takara, Japan). RT-qPCR was performed using SYBR premix Ex Taq (Takara, Japan), and ROX fluorescence was then analyzed using a Stratagene Mx3000p system (Agilent Technologies, USA).

Western‐Blot Assay {#Sec13}
------------------

Western blot assays were performed according to a previously published protocol^[@CR37]^. Briefly, cells were harvested before boiling in sample loading buffer for 10 min. Proteins were resolved by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE); after electrophoresis, the proteins were transferred to a PVDF membrane (Millipore, USA) and subjected to immunoblot analysis using the indicated antibodies. Proteins were visualized using an enhanced chemiluminescence method.

Capillary‐like Formation Assay {#Sec14}
------------------------------

The third passage of PDLSCs, Lenti-GFP/PDLSCs and Lenti-CXCL12-GFP/PDLSCs were seeded (2 × 10^4^ cells/well) in 96-well plates coated with Matrigel (BD Biosciences, USA). Images were captured at the different time points of the experiment.

Surgical craniotomies {#Sec15}
---------------------

The experimental protocols were approved by the Animal Welfare Committee of Shandong University. Classical porous β-TCP scaffolds (5 mm diameter and 2 mm depth) with an average pore size of 500 μm and 75% porosity were used as exosome carriers. Aliquots of 1 × 10^6^/mL PDLSCs were dropped onto each β-TCP scaffold under sterile conditions for at least 4 h.

Surgical procedures were performed as previously described. Briefly, 24 rats were anesthetized, a 1.5-cm sagittal incision was made in the scalp, and the calvarium was exposed by blunt dissection. Two bilateral 5-mm-diameter critical-sized calvarial defects were created using a dental trephine, and then scaffolds were implanted into the defects. The rats were randomly divided into four groups: β-TCP only group, Lenti-CXCL12-GFP/PDLSCs/β-TCP group, Lenti-GFP/PDLSCs/β-TCP group, and PDLSCs/β-TCP group. There were 6 rats in each groups (N = 6). Eight weeks after surgery, the rats were sacrificed, and crania were harvested and fixed in a 4% paraformaldehyde solution buffered with 0.1 M phosphate solution (pH 7.2) before further analysis.

Micro-CT Measurement {#Sec16}
--------------------

The specimens were harvested at 8 weeks postoperatively, and bone volume (BV) in the skull was assessed using a desktop microtomographic imaging system (MicroCT-80, Scanco Medical, Bassersdorf, Switzerland). Three-dimensional isosurface renderings were made for the visualization of bone with software. To obtain parameters of BV fraction and bone mineral densities (BMDs) in the defect areas, the gray-values of the voxels were stratified in a histogram running from 225 to 500 with a range of 25. Micro-CT measurements included BV to total bone volume (BV/TV) and local BMDs in the bone defect.

Histological Examination {#Sec17}
------------------------

The specimens were fixed in 10% formalin and embedded in paraffin, and 5-μm-thick sections were obtained. HE staining and immunohistochemical examination was performed.

Statistical Analyses {#Sec18}
--------------------

Statistics were presented as the mean ± s.d. An ANOVA with Tukey's post hoc test was used to assess statistical significance. Differences were considered significant at p-values of \<0.05 (\*p \< 0.05, when the lenti-CXCL12-GFP groups were compared with the Lenti-GFP group; ^\#^p \< 0.05, when the Lenti-GFP group was compared with the Control groups).
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